文献速递儿科与产科急症重症综合管理与镇静镇痛

博纳吐单抗治疗儿童标危B细胞急性淋巴细胞白血病

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
PubMed 文献 · N Engl J Med · 2024-12-07
一句话结论新诊断儿童标危B细胞急性淋巴细胞白血病(复发风险平均或更高)在化疗基础上加用博纳吐单抗两个28天周期,3年无病生存率96.0% vs 87.9%(P<0.001)。

这项3期随机对照试验纳入新诊断标危(美国国家癌症研究所标准)B细胞急性淋巴细胞白血病、复发风险平均或更高的儿童,随机接受单纯化疗或化疗加两个非序贯28天周期博纳吐单抗。数据与安全监察委员会基于首次中期疗效分析(1440例随机分组:单纯化疗722例、博纳吐单抗联合化疗718例)建议提前终止随机分组。中位随访2.5年,3年无病生存率博纳吐单抗联合化疗组96.0±1.2%、单纯化疗组87.9±2.1%(限制性平均生存时间差72天,95%CI 36~108,分层log-rank检验P<0.001)。

要点

  • 3年无病生存率:博纳吐单抗联合化疗96.0±1.2% vs 单纯化疗87.9±2.1%,限制性平均生存时间差72天(95%CI 36~108,P<0.001)。
  • 复发风险平均组3年无病生存率:博纳吐单抗联合化疗97.5±1.3% vs 单纯化疗90.2±2.3%;复发风险更高组分别为94.1±2.5% vs 84.8±3.8%。
  • 博纳吐单抗周期中3级及以上细胞因子释放综合征、癫痫发作和脓毒症罕见。
  • 复发风险平均组中,博纳吐单抗联合化疗组的非致命性脓毒症和导管相关感染总体发生率显著高于单纯化疗组。
  • 研究因首次中期疗效分析结果被数据与安全监察委员会建议提前终止随机分组。

适用人群与场景

  • 新诊断标危(按美国国家癌症研究所定义)B细胞急性淋巴细胞白血病儿童,且复发风险为平均或更高。
  • 纳入随机分组共1440例:单纯化疗722例,博纳吐单抗联合化疗718例。

处置流程与药物剂量

  • 博纳吐单抗组在化疗基础上接受两个非序贯28天周期的博纳吐单抗。

研究设计与关键结果

  • 3期随机对照试验,纳入新诊断标危B细胞急性淋巴细胞白血病、复发风险平均或更高的儿童,随机接受单纯化疗或化疗加两个非序贯28天周期博纳吐单抗;主要终点为无病生存。
  • 数据与安全监察委员会审查首次中期疗效分析(1440例随机分组:单纯化疗722例、博纳吐单抗联合化疗718例)后建议提前终止随机分组。
  • 中位随访2.5年,估计3年无病生存率博纳吐单抗联合化疗组96.0±1.2% vs 单纯化疗组87.9±2.1%,限制性平均生存时间差72天(95%CI 36~108),分层log-rank检验P<0.001。
  • 复发风险平均组3年无病生存率:博纳吐单抗联合化疗97.5±1.3% vs 单纯化疗90.2±2.3%;复发风险更高组:博纳吐单抗联合化疗94.1±2.5% vs 单纯化疗84.8±3.8%。
  • 博纳吐单抗周期中3级及以上细胞因子释放综合征、癫痫发作和脓毒症罕见;但复发风险平均组中,分配至博纳吐单抗联合化疗者的非致命性脓毒症和导管相关感染总体发生率显著高于分配至单纯化疗者。

证据类型、等级与局限

  • 证据类型:3期随机对照试验(AALL1731,ClinicalTrials.gov NCT03914625),由美国国立卫生研究院等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在新诊断儿童标危B细胞急性淋巴细胞白血病、复发风险平均或更高的患者中,化疗基础上加用博纳吐单抗显著改善无病生存。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.

METHODS: We conducted a phase 3 trial involving children with newly diagnosed standard-risk B-cell ALL who had an average or higher risk of relapse. Patients were randomly assigned to receive chemotherapy alone or chemotherapy plus two nonsequential 28-day cycles of blinatumomab. The primary end point was disease-free survival.

RESULTS: The data and safety monitoring committee reviewed the results from the first interim efficacy analysis, which included 1440 patients who had undergone randomization (722 to chemotherapy alone and 718 to blinatumomab and chemotherapy) and recommended early termination of randomization. At a median follow-up of 2.5 years, the estimated 3-year disease-free survival (±SE) was 96.0±1.2% with blinatumomab and chemotherapy and 87.9±2.1% with chemotherapy alone (difference in restricted mean survival time, 72 days; 95% confidence interval, 36 to 108; P<0.001 by stratified log-rank test). The estimated 3-year disease-free survival among patients with an average relapse risk was 97.5±1.3% with blinatumomab and chemotherapy and 90.2±2.3% with chemotherapy alone; among those with a higher relapse risk, the corresponding values were 94.1±2.5% and 84.8±3.8%. Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare during blinatumomab cycles, but the overall incidence of nonfatal sepsis and catheter-related infections was significantly higher among patients with an average relapse risk who had been assigned to receive blinatumomab and chemotherapy than among those assigned to receive chemotherapy alone.

CONCLUSIONS: Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of Health and others; AALL1731 ClinicalTrials.gov number, NCT03914625.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2024. PMID: 39651791. doi:10.1056/NEJMoa2411680

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。